These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31017125)

  • 1. Reaching 90-90-90: outcomes of a 15-year multi-country HIV workplace programme in sub-Saharan Africa.
    Boerma R; Schellekens O; Rinke de Wit TF; Wit FW; van der Borght S; Rijckborst H; Chukwumah P; Schilthuis H
    Antivir Ther; 2019; 24(5):363-370. PubMed ID: 31017125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.
    May M; Boulle A; Phiri S; Messou E; Myer L; Wood R; Keiser O; Sterne JA; Dabis F; Egger M;
    Lancet; 2010 Aug; 376(9739):449-57. PubMed ID: 20638120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018.
    Lecher SL; Fonjungo P; Ellenberger D; Toure CA; Alemnji G; Bowen N; Basiye F; Beukes A; Carmona S; de Klerk M; Diallo K; Dziuban E; Kiyaga C; Mbah H; Mengistu J; Mots'oane T; Mwangi C; Mwangi JW; Mwasekaga M; N'tale J; Naluguza M; Ssewanyana I; Stevens W; Zungu I; Bhairavabhotla R; Chun H; Gaffga N; Jadczak S; Lloyd S; Nguyen S; Pati R; Sleeman K; Zeh C; Zhang G; Alexander H
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(21):775-778. PubMed ID: 34043612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis.
    Taieb F; Madec Y; Cournil A; Delaporte E
    PLoS One; 2017; 12(4):e0174767. PubMed ID: 28426819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016.
    Lecher S; Williams J; Fonjungo PN; Kim AA; Ellenberger D; Zhang G; Toure CA; Agolory S; Appiah-Pippim G; Beard S; Borget MY; Carmona S; Chipungu G; Diallo K; Downer M; Edgil D; Haberman H; Hurlston M; Jadzak S; Kiyaga C; MacLeod W; Makumb B; Muttai H; Mwangi C; Mwangi JW; Mwasekaga M; Naluguza M; Ng'Ang'A LW; Nguyen S; Sawadogo S; Sleeman K; Stevens W; Kuritsky J; Hader S; Nkengasong J
    MMWR Morb Mortal Wkly Rep; 2016 Dec; 65(47):1332-1335. PubMed ID: 27906910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
    Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
    PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review.
    Adejumo OA; Malee KM; Ryscavage P; Hunter SJ; Taiwo BO
    J Int AIDS Soc; 2015; 18(1):20049. PubMed ID: 26385853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa.
    Van der Borght SF; Clevenbergh P; Rijckborst H; Nsalou P; Onyia N; Lange JM; de Wit TF; Van der Loeff MF
    Antivir Ther; 2009; 14(1):63-74. PubMed ID: 19320238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.
    Cornell M; Johnson LF; Wood R; Tanser F; Fox MP; Prozesky H; Schomaker M; Egger M; Davies MA; Boulle A;
    J Int AIDS Soc; 2017 Sep; 20(1):21902. PubMed ID: 28953328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Influence of Socioeconomic Environment on Paediatric Antiretroviral Treatment Coverage: Towards Closing Treatment Gaps in Sub-Saharan Africa.
    Adeyinka DA; Evans MR; Ozigbu CE; van Woerden H; Adeyinka EF; Oladimeji O; Aimakhu C; Odoh D; Chamla D
    Cent Eur J Public Health; 2017 Mar; 25(1):55-63. PubMed ID: 28399356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV/AIDS National Strategic Plans of Sub-Saharan African countries: an analysis for gender equality and sex-disaggregated HIV targets.
    Sherwood J; Sharp A; Cooper B; Roose-Snyder B; Blumenthal S
    Health Policy Plan; 2017 Dec; 32(10):1361-1367. PubMed ID: 28973358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a workplace HIV treatment programme in South Africa.
    Charalambous S; Innes C; Muirhead D; Kumaranayake L; Fielding K; Pemba L; Hamilton R; Grant A; Churchyard GJ
    AIDS; 2007 Jul; 21 Suppl 3():S73-8. PubMed ID: 17666964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The unique features of pediatric HIV-1 in sub-Saharan Africa.
    De Baets AJ; Ramet J; Msellati P; Lepage P
    Curr HIV Res; 2008 Jun; 6(4):351-62. PubMed ID: 18691033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term voluntary counseling and testing (VCT) uptake dynamics in a multicountry HIV workplace program in sub-Saharan Africa.
    Van der Borght SF; Schim van der Loeff MF; Clevenbergh P; Kabarega JP; Kamo E; van Cranenburgh K; Rijckborst H; Lange JM; Rinke de Wit TF
    AIDS Care; 2010 Feb; 22(2):195-205. PubMed ID: 20390498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries.
    Staveteig S; Croft TN; Kampa KT; Head SK
    PLoS One; 2017; 12(10):e0186316. PubMed ID: 29023510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.